Evidence map›Paper›PMID 22899340›Full record

ArticleInternational journal of hematology2012

Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.

Hui Zhi Low, Dorothee Hilbrans, Ingo G H Schmidt-Wolf, Harald Illges

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hui Zhi LowUniversity of Applied Sciences Bonn-Rhein-Sieg, Immunology and Cell Biology, von-Liebig-Str. 20, 53359 Rheinbach, Germany.
Dorothee Hilbrans
Ingo G H Schmidt-Wolf
Harald Illges
Hochschule Bonn-Rhein-Sieg · DEUniversity Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD21 is a 145-kDa membrane glycoprotein mainly expressed on B cells and follicular dendritic cells, and is involved in B-cell activation, survival and proliferation. CD21 can be cleaved to give soluble CD21 (sCD21), which is constantly shed in healthy persons. We show here that plasma sCD21 levels are higher, while B-cell surface CD21 expression levels are lower in B-cell chronic lymphocytic leukemia (B-CLL) patients, but not in multiple myeloma (MM) patients. High sCD21 levels in the blood are positively correlated to the number of cells with high CD21 surface expression and the relative amount of CD21 expressed on the B cells. B-CLL patients with swollen lymph nodes had higher amounts of CD21 high-expressing B cells, as well as CD21 low-expressing B cells, as compared to B-CLL patients without swollen lymph nodes.

Indexed as

AgedAged, 80 and overB-LymphocytesDisease ProgressionFemaleHumansImmunophenotypingLeukemia, Lymphocytic, Chronic, B-CellLymph NodesMaleMiddle AgedMultiple MyelomaNeoplasm StagingReceptors, Complement 3dReceptors, Complement 3d

Identifiers

PMID22899340
OpenAlexW1984821366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.